Abstract
TWO DRUGS are used as aids in the treatment of chronic alcoholism in Denmark, namely disulfiram (Antabuse) and calcium carbimide (Dipsan). An increase in the diphenylhydantoin content of the serum 1 was found in patients given this drug in combination with disulfiram. The administration of the usual therapeutic dose of disulfiram (400 mg daily) for nine days was followed by an increase in diphenylhydantoin content in the serum by 100% to 400%. The aim of this study was to determine if the rise in serum diphenylhydantoin caused by disulfiram is the result of inhibition of the conversion of diphenylhydantoin to 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH) in the liver. Furthermore, we wished to determine whether the administration of calcium carbimide causes an increase in the diphenylhydantoin content of the serum in patients with epilepsy who require therapy for chronic alcoholism. Material and Methods Six male patients who had been treated with diphenylhydantoin for
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
